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S U M M A R Y
Objective: Hepatitis C virus (HCV) is probably the leading cause of liver cirrhosis and hepatocellular
carcinoma globally. Diagnostic tools conventionally used for the detection and identiﬁcation of HCV
infection are technically demanding, time-consuming, and costly for resource-limited environments.
This study reports the development of the ﬁrst rapid loop-mediated reverse transcription isothermal
ampliﬁcation assay that rapidly detects and identiﬁes HCV genotypes in blood components.
Methods: RNA extracted from donor plasma and serum specimens was applied to a one-step reverse
transcription loop-mediated isothermal ampliﬁcation reaction performed with HCV-speciﬁc oligonu-
cleotides. Reactions were conducted at 63.5 8C for 30–60 min. The diagnostic characteristics of the assay
were investigated and validated with clinical specimens.
Results: Electrophoretic analysis of ampliﬁcation revealed detection and identiﬁcation of HCV genotypes
1–6. Positive ampliﬁcation revealed unique ladder-like banding patterns that identiﬁed each HCV
genotype. The assay demonstrated a sensitivity of 91.5% and speciﬁcity of 100%. Rapid naked-eye
detection of HCV infection was facilitated by observation of an intense ﬂuorescent glow of ampliﬁed
targets under UV illumination.
Conclusion: These diagnostic characteristics highlight the potential utility of this assay for the rapid
detection and genotype identiﬁcation of HCV infection in ﬁeld and point-of-care settings in endemic
regions and resource-limited environments.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Hepatitis C virus (HCV) is a single-stranded RNA virus of the
Flaviviridae family.1 Transmitted through modes including injec-
tion drug use, contaminated needle-stick injuries, and unsafe
blood transfusion, infection with HCV may lead to chronic active
hepatitis and hepatocellular carcinoma.2–4 Approximately 185 mil-
lion people are infected with HCV worldwide, with developing
countries of Sub-Saharan Africa, Asia, North and South America,
and the Middle East most affected.5–7
There are seven major genotypes of HCV with 67 subtypes
found in different regions of the world.8–10 Globally, HCV genotype* Corresponding author. Tel.: +1 240-421-5909.
E-mail address: dnyan@doctor.com (D.-C. Nyan).
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1 is the most common, accounting for about 46% of all infections.
This is followed by genotype 3, accounting for 22% of the global
HCV burden, and genotypes 2 and 4, each accounting for 13%.5–7
The detection of HCV infection in blood derivatives and the
identiﬁcation of the genotypes are therefore important in clinical
diagnostics and antiviral treatment, ensuring blood safety, and
providing epidemiological information about HCV prevalence.11–13
A plethora of molecular diagnostic methods have been designed
and used for the detection and genotyping of HCV infection. While
these tests are highly sensitive, they remain expensive and
laborious and require well-trained personnel, as well as sophisti-
cated laboratory facilities.14–17 Furthermore, the application of
these tests may be limited regarding their ability to detect and
simultaneously identify the speciﬁc HCV genotypes.18 Besides,
several (reverse transcription) loop-mediated isothermal ampliﬁ-
cation (RT)-LAMP assays have been designed for the detection ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Oligonucleotide sequences and color-matched illustration of set DN3 primers on the targeted HCV 50-NCR
Primer set Primer ID Nucleotide sequence (5–3 ) Length
DN1a DN1-F3 CGGGAGAGCCATAGTGGT 18
DN1-R3 TGGAAGAGTGCTCATGATGCACC 23
DN1-FI P TGAGCGGGTTTGATCCAATGTTTTTGCGGAACCGGTGAGTAC 42
DN1-RI P CCGCAAGACTGCTAGCCGAGTTTTACCGTATCAGGCAGTACCAC 44
DN1-LF TCGTCCTGGCAATTCCGG 18
DN1-LR TAGCGTTGGGTTGCGAAAG 19
DN2b DN2-F3 TCGAACAGCCTCCAGGACCC 20
DN2-R3 CACGGTCTACGAGACCTCC 19
DN2-FI P CGGGCATTGAGCGGGTTTATCCTTTTGGTGAGTACACCGGAATTGC 46
DN2-RI P CGCGAGACTGCTAGCCGAGTTTTTAGCAC CCTATCAGGCAGTAC 44
DN2-LF AAAGGACCCGGTCATCCC 18
DN2-LR GTCGCGAAAGGCCTTGTG 18
DN3c DN3-F3 GGCGACACTCCACCATGAAT 20
DN3-R3 CTATCAGGCAGTACCACAAGGC 22
DN3-FIP  CACTATGGCTCTCCCGGGAGTTTTCGTCTAGCCATGGCGTTAG   43 
DN3-RIP  GGAACCGGTGAGTACACCGGTTTT CCCAAATCTCCAGGCATTG A  44 
DN3-LF  AGGCTGCACGACACTCATA  19 
DN3-LR  GACCGGGTCCTTTCTTGGA  19 
 HCV 5 -NCR  (AF009606 )c 
      —DN3-F3—>  
1 GCCAGCCCCCTGATGGGGGCGACACTCCACCATGAATCACTCCCCTGTGAGGAACTACTG 
      —F2 of DN3-FIP—>    <—DN3-LF — 
61 TCTTCACGCAGAAAGCGTCTAGCCATGGCGTTAGTATGAGTGTCGTGCAGCCT CCAGGAC 
   <—F1c of DN3-FI P—     —R1c of DN3-RI P—>  
121 CCCCCCTCCCGGGAGAGCCATAGTGGTCTGCGGAACCGGTGAGTACACCGGAATTGCCAG 
   —DN3-LR—>        <—R2 of DN3-RIP — 
181 GACGACCGGGTCCTTTCTTGG ATAAACCCGCTCAATGCCTGGAGATTTGG GCGTGCCCCC 
          <—DN3-R3 — 
241 GCAAGACTGCTAGCCGAGTAGTGTTGGGTCGCGAAAGGCCTTGTGGTACTGCCTGATAGG 
HCV, hepatitis C virus; NCR, non-coding region.
GenBank accession numbers of HCV 50-NCR used for primer design: DQ480524a, Y13184b, and AF009606c.
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number of genotypes and rarely demonstrate genotype identiﬁca-
tion of the pathogens targeted for detection.19–25
Several reports have been published regarding RT-LAMP assays
that have utilized the HCV 50 non-coding region (50-NCR) for
primer design and the detection of HCV-RNA.22–25 Unfortunately,
these works have been limited to detection only and have
demonstrated no pattern formation of the bands, thereby
hindering the clear determination of true positive detection,
contamination, or cross-reactivity. Also, RT-LAMP assays tradi-
tionally rely on electrophoretic gel end-point analysis of banding
patterns to determine positive ampliﬁcation. Therefore, it is
important that laddering of RT-LAMP amplicons is arranged inclear and distinct patterns to enable easy analysis and interpreta-
tion of ampliﬁcation results.
This study reports the development of the ﬁrst RT-LAMP
method for the detection and simultaneous genotype identiﬁca-
tion of HCV genotypes 1–6. The assay is simple, sensitive, and
performed on the molecular basis of auto cycling strand-
displacement DNA synthesis, which produces long stem-loop
products of multiple inverted repeats under isothermal ampliﬁca-
tion.19–21 The ampliﬁcation process is rapid and accomplished in
less than 60 min, utilizing two thermostable enzymes and two to
three sets of oligonucleotides. The oligonucleotides target con-
served as well as sparsely polymorphic sequences in the 50-NCR of
the HCV genome26 (Table 1), producing distinctly clear banding
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identiﬁcation. In this study, a new approach to HCV detection
and genotype identiﬁcation is introduced and discussed.
2. Materials and methods
2.1. Nucleic acid standards and plasma panels
Quantiﬁed Armored RNA standards of HCV1a, HCV1b, and
HCV2ac, HIV-1B, dengue virus (DENV) 1, and West Nile virus
(WNV) were purchased from Asuragen (Austin, TX, USA). HCV
genotyping plasma panels of World Health Organization (WHO)
International Standard were used in the development of the assay.
The panels included HCV Worldwide AccuSet Performance Panel
0810-0173 (SeraCare, Milford, MA, USA), Worldwide HCV Perfor-
mance Panel WWHV303 (SeraCare, USA), and AcroMetrix HCV
Genotyping Panel (Applied Biosystems/Life Technologies, Grand
Island, NY, USA). Also, the hepatitis B virus (HBV) plasma panel of
WHO International Standard (Applied Biosystems/Life Technolo-
gies, USA) was used as the control in the development of the assay.
2.2. Design of oligonucleotide sequences
Full-length sequences of various HCV genotypes were obtained
from the GenBank database of the National Center for Biotechnol-
ogy Information (NCBI) and analyzed using CLUSTAL-W2. Primer
sets targeting the 50-NCR of the HCV genome were designed
manually and consisted of the following: forward inner primer
(FIP), reverse inner primer (RIP), loop forward primer (LF), loop
reverse primer (LR), forward outer primer (F3), and reverse outer
primer (R3). A ‘TTTT’ spacer was used to link the two sequences of
FIP (F1c and F2) and RIP (R1c and R2). The primers targeted
conserved as well as sparsely polymorphic nucleotide sequences in
the HCV 50-NCR. Several sets of primers were designed and
analyzed, and three sets designated as DN1, DN2, and DN3 were
used in this assay (Table 1). The oligonucleotides were synthesized
by Euroﬁns MWG Operon (Huntsville, AL, USA) and Integrated DNA
Technologies (Coralville, IA, USA).
2.3. Specimens and nucleic acid extraction
A total of 171 archival blood donor clinical specimens were
tested in order to evaluate the clinical applicability of the test. Total
RNA was extracted from healthy human plasma specimens
(n = 100) and clinical donor plasma specimens infected by HCV
(n = 65) that were pre-selected using the US Food and Drug
Administration (FDA)-approved Procleix test27 (packet insert) for
comparison. RNA was also isolated from HCV-3a clinical plasma
samples (n = 3; kindly provided by Dr J. Stapleton), HCV-4a clinical
serum specimens (n = 3; kind gift from Dr M. Ghany), and from the
HCV genotyping plasma panels. Extraction of RNA was performed
with the QiaAmp Viral RNA Mini Kit protocol (Qiagen, German-
town, MD, USA) with some modiﬁcations, as follows: approxi-
mately 200 ml of plasma and serum were used for RNA extraction,
while 4 ml of RNA-Secure (Ambion/Life Technologies, Grand Island,
NY, USA) were added to the 60-ml RNA elution to protect the
nucleic acid from degradation. Viral DNA, used as assay control,
was extracted from the HBV plasma panel (Applied Biosystems/
Life Technologies, USA) using the QiaAmp DNA Mini Kit (Qiagen,
USA) according to the manufacturer’s protocol. The eluted nucleic
acids were aliquoted and stored at 80 8C until needed for testing.
2.4. HCV diagnostic genotyping assay
Detection and identiﬁcation of HCV was performed by loop-
mediated reverse transcription isothermal ampliﬁcation in a 25-mltotal reaction mixture. The mixture comprised 12.5 ml of 2
mannitol acetate buffer (MAB),28 1 mM each of primers FIP and RIP,
0.6 mM each of primers LF and LR, 0.5 mM each of primers F3 and R3,
8 U of Bst DNA polymerase (New England Biolabs, MA, USA), 5 U of
cloned AMV reverse transcriptase, and 10 U of RNaseOUT
(Invitrogen,, MD, USA). An RNA template volume of 5 ml was
applied to the reaction. A no-template (water) control was included
in all experiments. Positive controls included known genotypes of
HCV-RNA standards. HIV, DENV, WNV, HBV DNA (OptiQuant-
AcroMetrix/Life Technologies, Benicia, CA, USA), and normal human
plasma were used as assay negative controls. Reactions were
performed at 63.5 8C for 30–60 min on a portable digital heat-block,
the MyBlock Mini Dry Bath (Benchmark Scientiﬁc, Edison, NJ, USA),
and terminated by placing the reaction tubes on ice.
2.5. Analysis of amplicons
Reaction products were analyzed by running 5 ml of ampliﬁca-
tion products on a 2.8% agarose gel prepared in 1 TBE (89 mM
Tris-base, 89 mM boric acid, 2 mM ethylenediaminetetraacetic
acid (EDTA); pH 8.0) and stained with GelRed (Phenix Research
Products, Candler, NC, USA). Products were electrophoresed for
50–55 min at 120 volts in 1 TBE buffer, visualized under a UV
transilluminator at 302 nm, and photographed with the G:BOX gel
documentation system (Syngene, Frederick, MD, USA). For rapid
acquisition of results, 0.5 ml of 10 GelGreen dye (Phenix Research
Products, USA) was added to 10 ml of ampliﬁcation products in the
tubes. The tubes were then visualized under a UV transilluminator
at 302 nm and photographed with an iPad-Air tablet camera
(Apple Inc., Cupertino, CA, USA) or a BlackBerry Z30 smartphone
camera (Research-In-Motion, Ontario, Canada). Electrophoretic
analysis of banding patterns and visual interpretation of ﬂuores-
cence intensity in the reaction tubes were performed by at least
three laboratory personnel.
2.6. Speciﬁcity and sensitivity studies
Assay speciﬁcity and the cross-reactivity of primers were
evaluated by testing the HCV oligonucleotides against nucleic acids
of HIV, DENV, WNV, and HBV. Primer sets were also evaluated for
their ability to produce banding patterns common to all HCV
genotypes tested, or to produce distinguishable ladder-like
banding patterns unique to each HCV genotype. Sensitivity and
the limit of detection (LOD) of the RT-LAMP genotyping assay were
evaluated by testing serial dilutions of quantitated HCV-RNA
ranging from 105 to 0.1 IU per reaction (IU/rxn). A probit analysis
was also conducted by testing 5–6 replicates of the HCV-RNA
dilutions (105 to 0.1 IU/rxn).
2.7. Assay inhibition studies
The detection of HCV-RNA was performed in the presence of
nucleic acids of other pathogens in order to investigate the ability
of the assay to detect its target without inhibition by co-puriﬁed
nucleic acid substrates. Hence, the target HCV-RNA (103 IU/rxn)
was ampliﬁed in an RT-LAMP reaction in the presence of either
HIV-RNA (106 IU/rxn) or HBV-DNA (105 IU/rxn), and with both HIV
and HBV nucleic acids combined.
2.8. Time-course of HCV-RNA detection
In order to determine the time-point at which HCV-RNA was
ampliﬁed, time-course experiments were conducted by testing
two higher dilutions of HCV-RNA (10 and 50 IU/rxn) at deﬁned
reaction time intervals (20, 30, 40, and 60 min). Negative control
reactions ran for 60 min.
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The clinical application of the HCV RT-LAMP genotyping assay
was evaluated by testing clinical specimens infected by HCV
(n = 71) and normal/healthy human plasma specimens (n = 100).
Total RNA was extracted from the specimens and 5–10 ml of RNA
was subjected to isothermal ampliﬁcation. Reaction products were
resolved on a 2.8% agarose gel to analyze the resulting banding
patterns that distinguish the HCV genotypes.
2.10. Detection of HCV-RNA with heat-treated plasma specimens
In order to evaluate the ability of the assay to amplify viral nucleic
acid without RNA isolation, 50 ml of standard quantitated plasma
specimens (OptiQuant-AcroMetrix/Life Technologies) were serially
diluted with normal human plasma. The dilutions were heated for
approximately 5–10 min at 33.5 8C. Next, 5 ml of heat-treated
materials ranging from 106 to 102 IU were applied directly to the
isothermal ampliﬁcation reaction for the detection of HCV-RNA.
3. Results
3.1. Detection and analysis of products
Total RNA extracts of HCV genotypes 1–6 were subjected to
isothermal ampliﬁcation. Electrophoretic analysis of reaction
products demonstrated positive ampliﬁcation of HCV-RNA by
primer sets DN1 and DN2. The oligonucleotides produced a ladder-
like banding pattern common to HCV genotypes 1–6, while the
assay reaction was negative to DENV, WNV, HIV, and HBV, as
conﬁrmed by the absence of a banding pattern (Figure 1A;
Supplementary Material Figure S1A). For rapid naked-eyeFigure 1. Detection, speciﬁcity, and identiﬁcation of HCV genotypes. (A) Results of 
oligonucleotide set DN1, but no detection of dengue virus (lane D) or West Nile virus (lane
HCV genotypes 1–6, but the absence of banding pattern in the no-template control (NTC
(HCV 1–6) demonstrated by an intense ﬂuorescent glow as compared with the negative co
ampliﬁcation using primer set DN3. Electrophoretic analysis showed the detection of al
genotype, as illustrated by the differentiating color lines. M = 100 bp marker; NTC = novisualization of the results, GelGreen DNA intercalating dye was
added to the reaction tubes, which revealed an intense ﬂuores-
cence glow in tubes with ampliﬁed RNA as compared with the no-
template control (NTC), DENV, WNV, HIV, and HBV (Figure 1B;
Supplementary Material Figure S1B).
3.2. Speciﬁcity and genotype identiﬁcation
The assay speciﬁcity and cross-reactivity of the primers were
evaluated by ampliﬁcation and gel electrophoretic analysis. As
observed on the gels, the primers detected only HCV-RNA, but
reacted negative to nucleic acids of DENV (or D), WNV (or W), HIV,
and HBV (Figure 1A; Supplementary Material Figure S1). Inter-
estingly, primer set DN3 reacted positive to HCV genotypes 1, 3, 4,
5, and 6, producing banding patterns of amplicons that were
unique to each genotype detected, although weakly positive for
HCV-3 (Figure 1C). Differences in banding patterns were identiﬁed
by keen observation of the pattern locations relative to the
molecular marker, size of the bands within the patterns, spacing of
each group of patterns, and the laddering-shift of the patterns, as
illustrated by the color lines between the duplicate samples
(Figure 1C). When clinical donor specimens were tested using
primer set DN3, the results revealed detection of HCV-1 and HCV-6
(Figure 2; Supplementary Material Figure S2 and Table S1).
3.3. Assay sensitivity
The assay sensitivity and LOD were determined by testing serial
dilutions of HCV-RNA (105–0.1 IU/rxn). The results of electropho-
retic analysis demonstrated detection of 10 IU/rxn of HCV-RNA
(Figure 3A). The addition of GelGreen ﬂuorescent dye to the
reaction tubes revealed a ﬂuorescent glow of decreasing intensityelectrophoresis showing positive ampliﬁcation of HCV genotypes 1–6 utilizing
 W). The results demonstrate the presence of similar ladder-like banding patterns in
), D, and W. (B) Rapid detection of targets by UV visualization of ampliﬁed targets
ntrols. (C) Duplicates of HCV genotypes 1, 3, 4, 5, and 6 were subjected to isothermal
l targets with differentiating ladder-like banding patterns unique to each detected
n-template control; NC = negative control; D = dengue virus; W = West Nile virus.
Table 2
Evaluation of assay diagnostic sensitivity and speciﬁcity
A. Probit data of replicates of HCV-RNA serial dilutions
HCV-RNA dilutions (IU) Number of
replicates
tested
Number of
positive
reactions
Percent
positive
(%)
105 6 6 100
104 5 5 100
103 5 5 100
102 5 5 100
50 5 4 80
10 5 2 40
1.0 5 0 0
0.1 5 0 0
B. Test of clinical specimens
HCV-positive
specimens
HCV-negative
specimens
Total
tested
Positive test 65 0 65
Negative test 6 100 106
Total specimens 71 100 171
C. Diagnostic test evaluation
Value 95% CI
Sensitivity (%) 91.5 82.5–96.8
Speciﬁcity (%) 100 96.3–100
Positive predictive value (%) 100 94.4–100
Negative predictive value (%) 94.3 88.0–97.8
Positive likelihood ratio 0 0
Negative likelihood ratio 0.08 0.04–0.18
HCV, hepatitis C virus; CI, conﬁdence interval.
Figure 2. Diagnostic speciﬁcity and identiﬁcation of HCV genotypes in clinical
specimens. In order to evaluate the clinical utility of the assay, total RNA extracted
from clinical specimens was subjected to isothermal ampliﬁcation utilizing primer
set DN3. Electrophoretic analysis of the ampliﬁed products demonstrated the
detection of HCV-1 (lane 3) and HCV-6 (lane 5) with distinct ladder-like banding
patterns. Note the differentiation in banding pattern (aided by illustrative color
dots). Lane 1 = NTC (no template control); lane 2 = PC (positive control HCV-1); lane
3 = HCV-1 clinical specimen; lane 4 = HCV-5 positive control; lane 5 = HCV-6
clinical specimen; M = 100-bp marker; lanes 6–9 = NP (normal plasma specimens).
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Probit test of HCV-RNA replicates demonstrated a 100% detection
rate for 105, 104, 103, and 102 IU, an 80% detection rate for 50 IU,
and a 40% detection rate for 10 IU; 1 IU and 0.1 IU of HCV-RNA were
not detected (Table 2A).
3.4. Detection interference studies
The ability of the assay to speciﬁcally detect HCV nucleic acid in
the presence of non-target nucleic acids was evaluated. Agarose gel
analysis of the reaction products revealed no inhibition of HCV-
RNA ampliﬁcation, as demonstrated by the presence of ladder-like
banding patterns in lanes 5, 6, and 7; the resulting banding
patterns were similar to banding patterns observed in the HCV-
positive control in lane 4 (Figure 4). No banding pattern was
observed in the HIV-RNA and HBV-DNA negative control reactions
in lanes 1, 2, and 3, respectively (Figure 4).
3.5. Time-course of detection
In order to determine the time-point at which ampliﬁcation of
HCV-RNA occurred, 10 and 50 IU of RNA were tested in theFigure 3. Assay detection sensitivity. Sensitivity was evaluated using serial
dilutions of HCV-RNA. The assay detected down to 10 IU/rxn of RNA (lane 8) and
demonstrated ﬂuorescence of decreasing intensity corresponding to the amount of
nucleic acid detected (lanes 3–8). NTC = no-template control; NC = negative plasma
control; M = 100-bp marker; HCV = hepatitis C virus.isothermal ampliﬁcation reaction at designated time-points.
Results of the electrophoretic analysis of reaction products
revealed ampliﬁcation of 10 IU/rxn of RNA at 60 min, while
ampliﬁcation of 50 IU/rxn was observed at 40 min (Figure 5).
3.6. Detection and identiﬁcation of HCV in clinical specimens
In order to determine the clinical applicability of the RT-LAMP
genotyping assay, total RNA was extracted from 171 clinical donor
specimens and tested using primer set DN3. Of the 71 HCV-positive
clinical donor specimens tested, the assay detected a total ofFigure 4. Detection of HCV in the presence of other viruses. HCV-RNA was tested
against the background of HIV and HBV nucleic acids. Electrophoretic results of
ampliﬁcation showed the detection of HCV-RNA in lanes 5–7 in the presence of HIV-
RNA and HBV-DNA; this is conﬁrmed by the presence of ladder-like banding
patterns identical to the HCV-positive control in lane 4 and the absence of banding
pattern in lanes 1–3. NTC = no-template control; HIV = human immunodeﬁciency
virus (106 IU/rxn); HBV = hepatitis B virus (105 IU/rxn); HCV = hepatitis C virus (103
IU/rxn); M = 100-bp marker.
Figure 5. Assay time-point of HCV-RNA detection. The time-point at which
detection occurs was evaluated using 50 and 10 IU/rxn of HCV-RNA in the
ampliﬁcation reaction at deﬁned time intervals over a 60-min period.
Electrophoretic analysis demonstrated the detection of 50 IU of HCV-RNA at the
40-min time-point, while 10 IU/rxn was detected at the 60-min time-point.
NTC = no-template control; M = 100 bp marker.
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positive for HCV-1, two plasma specimens tested positive for HCV-6,
two of the known HCV-3 serum specimens tested positive, and the
three known HCV-4 plasma specimens also tested positive, while a
total of six HCV-infected specimens reacted negative. All healthy
human plasma specimens (n = 100) tested negative (Figure 2,
Table 2B; Supplementary Material Figure S2 and Table S1). As
presented in Table 2C, the assay demonstrated a diagnostic
sensitivity of 91.5% with a conﬁdence interval (CI) of 82.5–96.8%,
while the speciﬁcity was 100% with a 95% CI of 96.3–100%.
3.7. Detection of HCV-RNA with heat-treated plasma specimens
The assay was also investigated for its ability to amplify viral
nucleic acid from heat-treated specimens without RNA extraction.
When serial dilutions of heated plasma specimens were tested in
the ampliﬁcation reactions, electrophoretic results demonstrated
the detection of HCV-RNA (106–104 IU/rxn), as conﬁrmed by the
presence of banding patterns (Supplementary Material Figure S3).
4. Discussion
HCV is a major health care problem worldwide. The detection of
HCV and genotype identiﬁcation provide important insights into the
clinical progression of liver disease, the response to antiviral
therapies, and the dynamics of the HCV global epidemiological
proﬁle. This study demonstrated the performance of a speciﬁc and
simple isothermal ampliﬁcation assay for the rapid detection and
genotype identiﬁcation of HCV infection in plasma and serum. This
work describes the ﬁrst RT-LAMP assay that detects six HCV
genotypes using single primer sets such as DN1 and DN2. This assay
demonstrates advantages over labor-intensive methods that require
heavy equipment and multiple diagnostic steps for HCV detection
and genotype identiﬁcation.29–33 Conducted as a one-step procedure,
this assay also obviates the need for extra cDNA synthesis and
restriction digest steps for genotype identiﬁcation. In this assay, both
the synthesis and ampliﬁcation of HCV-RNA were performed in a
single reaction tube, using a single temperature. Additionally, the
assay detected and distinguished the HCV genotypes without
requiring post-ampliﬁcation genotyping procedures such as
restriction enzyme analysis, reverse hybridization, or nested RT-
PCR.25,29–33 Moreover, this assay successfully ampliﬁed HCV-RNA
utilizing heated specimens without conventional RNA extraction
(Supplementary Material Figure S3). This method of substrate
preparation enhances the rapidity of detection and may provide a
cost-saving approach for laboratories in resource-limited settings.Notwithstanding its time-saving nature and cost-effectiveness,
further improvements to this method of template preparation are
required.
HCV circulates in various geographic regions of the world with
high prevalence.8–10 Thus in most developed countries, blood
donor screening for HCV infection and surveillance are performed
using state-of-the-art tools for early diagnosis to ensure the safety
of the blood supply and to monitor the epidemiological distribu-
tion pattern of the virus. In contrast, this poses a challenge in
developing countries where diagnostic resources are limited or
unavailable. With its demonstrated diagnostic characteristics, the
RT-LAMP assay reported in this study may thus contribute to
addressing the diagnostic needs of resource-limited environments
and underserved communities (Table 2).
The HCV assay demonstrated a sensitivity of approximately
10 IU/rxn of extracted RNA (Figure 3), making it potentially capable
of early diagnosis of HCV infection. Also, the assay revealed a good
analytical speciﬁcity without cross-reacting with other viral
pathogens, as the assay detection of HCV-RNA was not inhibited
by the presence of HBV or HIV nucleic acids (Figure 4). Moreover,
the assay detected HCV-RNA in 65 of 71 infected clinical
specimens, thus revealing a 91.5% diagnostic sensitivity
(Table 2C; Supplementary Material Table S1). Also, the probit
data showed a 100% detection rate for 102 IU and an 80% detection
rate for 50 IU of HCV-RNA at the lower dynamic range of the assay
(Table 2A). These results are in agreement with previously
published reports of (RT)-LAMP sensitivity and speciﬁcity.21,24,28
This work utilized the 50-NCR of the HCV genome for primer
design due to its conserved nature across HCV genotypes, thus
facilitating the detection of all HCV genotypes tested. This work also
exploited the sparse nucleotide polymorphism present within the
HCV 50-NCR for genotype identiﬁcation, as revealed by the
electrophoretic differences in banding patterns of the detected
targets (Figure 1C). When evaluated with clinical donor specimens,
the test identiﬁed specimens that were positive for HCV genotypes
1 and 6 (Figure 2; Supplementary Material Figure S2 and Table S1).
Collectively considered, these results have demonstrated the
potential capability of this isothermal assay for speciﬁc detection
and identiﬁcation of HCV genotypes. Although a demonstrated proof
of concept, this assay would beneﬁt from further evaluation in a ﬁeld
setting with a larger number of clinical samples in order to improve
its diagnostic and analytical characteristics.
A unique characteristic of this RT-LAMP genotyping assay is its
high speciﬁcity, not only due to the absence of cross-reactivity
with other pathogens, but by its demonstration of clearly distinct
electrophoretic laddering patterns of the targeted HCV genotypes.
It was consistently observed that the loop primers play a critical
role in banding pattern formation (data not shown – to be
published elsewhere) and primarily generate the resulting
differences in laddering patterns. This study therefore postulates
that the loop primers may have utilized the sparsely existing
nucleotide diversity within the conserved 50-NCR to generate the
differences observed in laddering pattern (Figure 1C, Figure 2;
Supplementary Material Figure S1).
The role of genotypes in the progression of HCV infection and
liver diseases is well documented. For example, HCV genotypes 1b
and 3 are reportedly associated with more severe liver diseases,
while the HCV response to antiviral therapies may also vary by
genotype.34–38 This highlights the therapeutic implications of
genotype as a critical factor when implementing individualized
therapies. With the exception of HCV-2 and HCV-7 RNA standards,
which were unavailable at the time of further investigation, this
assay successfully distinguished several HCV genotypes utilizing
the electrophoretic banding pattern (Figure 1C). Also, besides
testing HCV-1a and 1b, this assay did not investigate different
subtypes of the other genotypes tested due to the unavailability of
D.-C. Nyan, K.L. Swinson / International Journal of Infectious Diseases 43 (2016) 30–3636said test materials. Notwithstanding this drawback, this simple
diagnostic method may empower health care providers delivering
services in underserved environments, mainly in developing
countries; the demonstrated rapidity of the assay, amplifying
approximately 50 IU of HCV-RNA in less than 60 min, may
contribute to timely clinical decision-making (Figure 5). However,
additional studies including ﬁeld trials are warranted for further
evaluation and improvement of the diagnostic capabilities of this
assay.
In conclusion, the data presented in this study demonstrate a
reverse transcription isothermal ampliﬁcation assay with the
capability of detecting HCV infections at the genotypic level. Due to
its sensitivity, speciﬁcity, and lack of requirements for expensive
equipment, this assay is potentially suitable for ﬁeld and point-of-
care use in resource-limited settings and HCV-endemic regions of
the world.
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